ClinicalTrials.gg
Status unknownNCT05705635Updated Jan 31, 2023

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

A Phase 2 interventional study of Docetaxel for injection (Albumin-bound) and Taxotere in Gastric Adenocarcinoma and Adenocarcinoma of Gastroesophageal Junction, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Read the detailed description

One hundred patients with locally advanced or metastatic gastric adenocarcinoma or gastric esophageal junction adenocarcinoma will be randomly assigned to the test group or the control group. All patients will receive Docetaxel for injection (Albumin-bound) or Taxotere for treatment until disease progression. Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.

02

Conditions studied

  • Gastric Adenocarcinoma
  • Adenocarcinoma of Gastroesophageal Junction

Keywords

  • gastric adenocarcinoma, gastroesophageal junction adenocarcinoma,Docetaxel,Albumin-bound
03

In context

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-75 (inclusive) (Whichever is on the day of signing the form).
  2. Willing to sign the informed consent form, willing and able to follow the program to accept visits, treatment and laboratory tests.
  3. Gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction confirmed by histology or cytology.
  4. Locally advanced or gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction after receiving at least systematic treatment (defined as platinum/fluorouracil containing dual drug chemotherapy, with or without immunotherapy).
  5. Previous history with positive Her-2 expression requires anti-Her-2 medication; unknown Her-2 expression should define Her-2 status before enrollment.
  6. Adequate main organ function.
  7. (ECOG) score 0-1.
  8. Expected lifetime≥ 3 months.
  9. Female patients of childbearing age must have a negative serum pregnancy test within 7 days prior to randomization; patients must agree to take adequate from signing of ICF through 6 months after last dose, during which time women are not breastfeeding; male patients must agree to contraception and refuse sperm donation.
  10. At least one assessable lesion according to V1.1; The area should not have received radiotherapy in the past, or there is evidence that the lesion has made definite progress after radiotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Other active malignant tumors in the first 5 years of randomization.
  2. Uncontrolled serous cavity effusion requiring frequent drainage or medical intervention within 7 days before randomization.
  3. Patients with central nervous system .
  4. Patients whose previous medical history shows dMMR/MSI-H and who have not received immunotherapy in the past are not suitable for enrollment, and those whose dMMR/MSI status is unknown need to clarify the status before enrolment.
  5. Patients who have used paclitaxel/docetaxel in the past (except patients with disease progression more than one year after /adjuvant treatment with paclitaxel/docetaxel).
  6. History of serious cardiovascular disease within 6 months before randomization.
  7. History of gastrointestinal perforation and/or fistula within 6 months before randomization.
  8. Hypertension with poor control during the screening period.
  9. Patients with active , or .
  10. Patients with severe chronic or active infections that require systemic antimicrobial, antifungal, or antiviral therapy.
  11. Patients with gastrointestinal obstruction and active inflammatory bowel disease within 28 days before randomization.
  12. Toxic reaction caused by any previous treatment has not recovered to level 1 or below (CTCAE5.0).
  13. Major organ surgery (except puncture ) within 28 days before randomization.
  14. Have received chemotherapy, radiotherapy, targeted therapy, immunotherapy or other anti-tumor treatment of clinical research drugs within 28 days before randomization.
  15. Have received traditional Chinese medicine with anti-tumor indications within 14 days before randomization.
  16. Have received powerful inhibitor or inducer within 14 days before randomization.
  17. Allergic to and / or to albumin or docetaxel.
  18. Known allergy and/or contraindication to .
  19. Patients with psychiatric neurological disorders that may affect trial adherence, or patients with a history of drug dependence / alcohol dependence.
  20. Other situations that the researcher thinks are not suitable for participating in this study.
  21. Patients participated in another clinical study at the same time, unless it is an observational (non intervention) clinical study or is in the follow-up period of an intervention study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Docetaxel for Injection (Albumin-bound)

    Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.

    Drug: Docetaxel for injection (Albumin-bound)

  • Active comparator
    Taxotere

    Taxotere will be administrated by intravenous infusion once every 3 weeks.

    Drug: Taxotere

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free-Survival (PFS)

    The duration is from the randomized time to disease progression or death due to any reason.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    The primary endpoint is objective response rate,which equals CR+PR.

    Time frame: Up to approximately 2 years

  2. Disease control rate (DCR)

    The primary endpoint is Disease Control rate,which equals CR+PR+SD.

    Time frame: Up to approximately 2 years

  3. Duration of Response (DoR)

    The time from the first assessment of tumor as CR or PR to the first assessment as PD or death from any cause

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost

    Time frame: Up to approximately 2 years

  5. Incidence of AE and SAE

    Time frame: Up to approximately 2 years

Other outcomes

  1. Plasma concentration of docetaxel (free and total)

    Time frame: At the end of Cycle 1(each cycle is 21 days)

07

Study locations

1 of 1 sites recruiting
  • Ethics Committee of Sun-Yat-Sen University Cancer Center
    Guangzhou, China
    Recruiting
    • Ruihua Xu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for May 2023, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Jan 31, 2023
StartActual
Jan 13, 2023
Primary completionEst.
May 2023
CompletionEst.
Dec 2024
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05705635
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Jan 13, 2023
Primary completion
May 2023 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 31, 2023

Study contacts

Ruihua Xu
Contact
xurh@sysucc.org.cn
+86-20-87343468
Ruihua Xu
study chair · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion